![]() |
产地 | 中国 |
品牌 | Chemstan |
货号 | CS00472 |
保存条件 | store at -80℃ |
用途 | 仅用于科研用途 |
应用范围 | |
抗原来源 | CHO cells |
CAS编号 | 1803171-55-2 |
保质期 | 一年 |
抗体名 | Ravulizumab ( 雷夫利珠单抗 ) |
是否单克隆 | |
克隆性 | |
靶点 | C5[Homo sapiens] |
适应物种 | |
形态 | |
宿主 | |
标记物 | |
包装规格 | 100μg |
纯度 | % |
亚型 | |
标识物 | |
浓度 | 95% |
免疫原 | |
是否进口 | 否 |
货号(Catalog No.)
CSD00472
通用名INN
Ravulizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.
别名(Alternative names)
ALXN-1210,ravulizumab-cwvz
靶点;物种(Specificity target name;species)
C5[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG2-G4-kappa
化学信息
CAS
1803171-55-2
存储条件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .